Pharmacotherapy of large B-cell lymphoma

Expert Opinion on Pharmacotherapy
Maricer P Escalón, I S Lossos

Abstract

Constituting approximately 30% of lymphoid malignancies, diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma in adults worldwide. The clinical and biologic heterogeneity that exists in DLBCL suggests that this entity might actually be comprised of several distinct neoplasms that could require different therapeutic approaches. DLBCL was considered incurable until combination chemotherapy became available. Current treatment strategies for the treatment of untreated and relapsed advanced-stage DLBCL are reviewed; novel treatments for DLBCL are discussed. Relevant literature was identified using the PubMed search engine and by reviewing abstracts from major conference proceedings. Recently, novel therapeutic strategies, including the incorporation of immunotherapy to combination chemotherapy, have improved outcome for patients with DLBCL with cure rates exceeding 50%, especially in younger patients.

References

Jan 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·T F TedderH Saito
Sep 1, 1994·Immunology Today·T F Tedder, P Engel
Oct 21, 1993·The New England Journal of Medicine·O W PressB Porter
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Jun 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W S VelasquezF Cabanillas
Jul 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A RodriguezW Velasquez
Apr 1, 1996·American Journal of Clinical Pathology·A Carbone, A Gloghini
Jan 2, 1997·Bone Marrow Transplantation·M de LimaR E Champlin
Apr 1, 1997·Bone Marrow Transplantation·M de Magalhaes-SilvermanE Ball
May 15, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N Mounier, C Gisselbrecht
May 20, 1999·Journal of Leukocyte Biology·M Degli-Esposti
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A ShippB Coiffier
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C H MoskowitzA D Zelenetz
Jan 27, 2000·Journal of Leukocyte Biology·C van Kooten, J Banchereau
Jun 28, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J P RadichF R Appelbaum
Dec 29, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·I W FlinnR F Ambinder
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthF Anthony Greco
Nov 21, 2002·Journal of Experimental Therapeutics & Oncology·John L MarshallMichael J Hawkins
Mar 26, 2003·Drug Discovery Today·Julian Adams
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maurizio MartelliSante Tura
Apr 30, 2003·Seminars in Oncology·Alessandra Cesano, Urte Gayko
Jun 5, 2003·Nature Medicine·Napoleone FerraraJennifer LeCouter
Jul 26, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M P GoetzC Erlichman
Aug 7, 2003·Current Opinion in Pharmacology·Shile Huang, Peter J Houghton
Oct 29, 2003·Cancer Control : Journal of the Moffitt Cancer Center·Paul G RichardsonKenneth C Anderson
Dec 12, 2003·Cancer Cell·Charles L Sawyers
Mar 17, 2004·Cancer·Barbara ProFernando Cabanillas
Mar 17, 2004·Biochimica Et Biophysica Acta·Amere Subbarao SreedharPéter Csermely
Mar 20, 2004·Pharmacology & Therapeutics·Amere Subbarao Sreedhar, Peter Csermely
Mar 26, 2004·Seminars in Oncology·Christian Gisselbrecht, Nicolas Mounier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.